Net Product Revenue was Syndax Pharmaceuticals’s largest product and service line in fiscal 2025, bringing in $124.84M of $172.35M (72%).
| Product and Service | FY 2024 | FY 2025 |
|---|---|---|
| Net Product Revenue | $7.68M | $124.84M |
| Collaboration Revenue | — | $42.37M |
| Milestone Revenue | $16.00M | $5.14M |
| Total | $23.68M | $172.35M |
Syndax Pharmaceuticals brought in $172.35M from its three product and service lines in fiscal 2025, the year ended December 31, 2025. Syndax Pharmaceuticals regrouped these lines after fiscal 2024, so the total does not compare directly with that year's $23.68M. Net Product Revenue was the largest at $124.84M (72.4%), ahead of Collaboration Revenue at $42.37M (24.6%) and Milestone Revenue at $5.14M (3.0%).
Compared with fiscal 2024, Net Product Revenue grew 1,525.6% to $124.84M, while Milestone Revenue fell 67.9% to $5.14M.
Syndax Pharmaceuticals began breaking out Collaboration Revenue in fiscal 2025, when it brought in $42.37M.
Syndax Pharmaceuticals (SNDX) reports its revenue by product and service. In fiscal 2025, Net Product Revenue was its largest product and service line, bringing in $124.84M (72.4% of the total), followed by Collaboration Revenue at $42.37M (24.6%).
Net Product Revenue was Syndax Pharmaceuticals' largest product and service line in fiscal 2025, bringing in $124.84M, or 72.4% of the $172.35M total across its three product and service lines.
Every figure comes from Syndax Pharmaceuticals' annual financial filings, as reported. Each line keeps the name Syndax Pharmaceuticals gives it, and years follow its fiscal calendar.
Syndax Pharmaceuticals' revenue by product and service goes back to fiscal 2024, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.